Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain
Rachel E Miller, Anne-Marie Malfait, Joel A Block, Rachel E Miller, Anne-Marie Malfait, Joel A Block
Abstract
Blockade of nerve growth factor (NGF) with antibodies is a promising strategy for treatment of chronic pain associated with osteoarthritis (OA). This narrative review describes the current status of NGF-blockade for the treatment of OA pain. We summarise briefly current evidence for the efficacy and risks of anti-NGF blockade. Two anti-NGF antibodies, tanuzemab and fasinumab, are in active development, with tanuzemabclose to completing Phase 3 trials in preparation for an application for approval for clinical use.
Conflict of interest statement
Conflict of Interest Statement:
Dr. Block has served as an investigator on Pfizer-sponsored clinical trials of tanezumab for OA.
Dr. Malfait has served on a scientific advisory board for Pfizer/Eli Lily and for Regeneron.
Dr. Miller has no conflicts.
Source: PubMed